research Corticotropin-releasing hormone: An autocrine hormone that promotes lipogenesis in human sebocytes
CRH promotes fat production in skin cells, affecting conditions like acne.
Search
forProducts matching "no release"
Tracking 2 products like 125 Polaris Research NR08 7% and 165 Urimax D (Tamsulosin HCl/Dutasteride 0.4mg/0.5mg) from by companies like Minoxidil Express and Inhouse Pharmacy. View all 2 products »Clinics
6 / 9 results- 8Hair TransplantRobert Reese, DOAustin, TX · US
- 69
Hair TransplantRenesse Clinic - Transplante Capilar com Zero Raspagem de Cabelo em Marília!Marília, SP · BR - 28
Hair Loss TreatmentsRelaxed and Natural Hair StudioIrving, TX · US - 18Hair Loss TreatmentsReese Hair RestorationBloomington, MN · US
- 10Hair TransplantReverseYasenevo · RU
- 19Hair Loss TreatmentsReverse Aesthetic, Dermatology, Hair Restoration Clinic Lekki, Victoria IslandLagos · NG
Research
5 / 1000+ resultsresearch Corticotropin releasing hormone and the skin
CRH in the skin acts like the body's stress response system, affecting cell behavior and immune activity.
research dsRNA Released by Tissue Damage Activates TLR3 to Drive Skin Regeneration
Damage to skin releases dsRNA, which activates TLR3 and helps in skin and hair follicle regeneration.
research Thyrotropin releasing hormone (TRH): a new player in human hair‐growth control
TRH stimulates human hair growth and extends the hair growth phase.
research In vivo promoted growth of mice hair follicles by the controlled release of growth factors
Controlled release of growth factors in hydrogels improved hair growth in mice.
Community Join
5 / 1000+ resultscommunity 30 new hair per cm by extended release minoxidil
Extended-release minoxidil shows promise for hair regrowth, potentially adding 30 new hairs per cm, but concerns about side effects like increased body hair and shortness of breath remain. Users discuss combining it with finasteride or dutasteride for better results, while some express skepticism about it being a complete cure.
community Veradermics VDPHL01 Topline Results for Extended-Release Oral Minoxidil
Extended-release oral minoxidil (VDPHL01) shows promising results for hair growth with improved safety, achieving significant hair count increases and minimal side effects compared to placebo. The treatment is designed to maintain effective concentrations while reducing side effects, making it a safer option for those who cannot tolerate standard minoxidil.
community European release of clascoterone
Clascoterone's European release is expected in Q4 2026, with FDA approval anticipated by mid-2027. The discussion includes questions about the approval timeline and potential acceleration due to unmet needs.
community Pyrilutamide release in Europe?
User asks about Pyrilutamide release in Europe, specifically Germany, and considers importing it from China. No specific treatments mentioned.
community Massive study on finasteride side effects released
The release of a study on 5a-reductase inhibitors (finasteride and dutasteride) which showed an increased risk of depression, dementia, decreased libido, and reduced semen load as potential side effects; discussion around other forms of hair loss treatments such as topical minoxidil, RU58841, or opting to accept baldness; and advice to consider professional help for deeper issues related to hair loss.
Experts
3 / 3 results
Learn
— no results